Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Current Investments (2016 - 2025)

Ascendis Pharma A's Cash & Current Investments history spans 8 years, with the latest figure at $429.8 million for Q4 2023.

  • For Q4 2023, Cash & Current Investments fell 42.72% year-over-year to $429.8 million; the TTM value through Dec 2023 reached $429.8 million, down 42.72%, while the annual FY2023 figure was $432.1 million, 44.26% down from the prior year.
  • Cash & Current Investments for Q4 2023 was $429.8 million at Ascendis Pharma A, down from $750.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $857.0 million in Q4 2020 and bottomed at $429.8 million in Q4 2023.
  • The 5-year median for Cash & Current Investments is $750.3 million (2022), against an average of $695.9 million.
  • The largest annual shift saw Cash & Current Investments surged 108.74% in 2019 before it tumbled 42.72% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $662.0 million in 2019, then increased by 29.45% to $857.0 million in 2020, then dropped by 8.96% to $780.3 million in 2021, then fell by 3.83% to $750.3 million in 2022, then crashed by 42.72% to $429.8 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Cash & Current Investments are $429.8 million (Q4 2023), $750.3 million (Q4 2022), and $780.3 million (Q4 2021).